Autolus

About

Autolus is a biopharmaceutical company focused on T-cell programming and manufacturing technology.

London,England,United Kingdom
251 - 500
https://www.autolus.com

Highlights

Details

Last Funding Type: Post-IPO Equity
Last Funding Money Raised: £122.50M
Industries: Biopharma,Biotechnology,Medical,Pharmaceutical
Founded date: Jan 1, 2014
Number Of Employee: 251 - 500
Operating Status: Active
Stock Symbol: nasdaq:AUTL
Legal Name: Autolus Therapeutics plc
Also Known As: Autolus Therapeutics

Autolus Therapeutics is working on next-generation programmed T cell treatments for the treatment of cancer.

The company's pipeline includes Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus was established in 2014 by Tim Funnell and Martin Pule in London, England.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

10

£192.50M $530M

Autolus has raised a total of £192.50M $530M in funding over 2 rounds. Their latest funding was raised on Dec 8, 2022 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 8, 2022	Post-IPO Equity	£122.50M	—	—	—	Detail
Nov 8, 2021	Post-IPO Equity	$250M	1	Blackstone Group	—	Detail
Feb 10, 2021	Post-IPO Equity	$100M	—	—	—	Detail
Sep 17, 2019	Post-IPO Equity	—	1	PPF Group	—	Detail
Apr 11, 2019	Post-IPO Equity	$100M	—	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

6

10

Autolus is funded by 10 investors. Blackstone Group and PPF Group are the most recent investors.

Investor Name	Lead Investor	Funding Round
Blackstone Group	Yes	Post-IPO Equity
PPF Group	Yes	Post-IPO Equity
Cormorant Asset Management	Yes	Series C
4BIO Capital	—	Post-IPO Equity
Arix Bioscience	—	Series C
GV	—	Series C
Nextech Invest	—	Series C
Syncona Partners LLP	—	Series C
UCLB	—	Series C
Woodford Investment Management	—	Series C